Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Clinical trial NCT04511130 · TERMINATED
Trial details
- NCT number
- NCT04511130
- Sponsor
- Marker Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-14
- Primary completion
- 2024-03-01
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.